@article{ce8e73ce7e6f444ea921dddabbd30476,
title = "The Polyploid State Plays a Tumor-Suppressive Role in the Liver",
abstract = "Most cells in the liver are polyploid, but the functional role of polyploidy is unknown. Polyploidization occurs through cytokinesis failure and endoreduplication around the time of weaning. To interrogate polyploidy while avoiding irreversible manipulations of essential cell-cycle genes, we developed orthogonal mouse models to transiently and potently alter liver ploidy. Premature weaning, as well as knockdown of E2f8 or Anln, allowed us to toggle between diploid and polyploid states. While there was no detectable impact of ploidy alterations on liver function, metabolism, or regeneration, mice with more polyploid hepatocytes suppressed tumorigenesis and mice with more diploid hepatocytes accelerated tumorigenesis in mutagen- and high-fat-induced models. Mechanistically, the diploid state was more susceptible to Cas9-mediated tumor-suppressor loss but was similarly susceptible to MYC oncogene activation, indicating that polyploidy differentially protected the liver from distinct genomic aberrations. This suggests that polyploidy evolved in part to prevent malignant outcomes of liver injury. Most liver cells are polyploid, but the functional role of wholesale genome duplications is unknown. To interrogate liver polyploidy function without irreversible manipulations of cell-cycle genes, Zhang et al. developed models to transiently alter ploidy, finding that polyploidy reduces tumor development by buffering against tumor-suppressor loss of heterozygosity.",
keywords = "Anln, E2f8, cytokinesis, hepatocellular carcinoma, liver cancer, mouse model, polyploidy",
author = "Shuyuan Zhang and Kejin Zhou and Xin Luo and Lin Li and Tu, {Ho Chou} and Alfica Sehgal and Nguyen, {Liem H.} and Yu Zhang and Purva Gopal and Tarlow, {Branden D.} and Siegwart, {Daniel J.} and Hao Zhu",
note = "Funding Information: We thank H. Yu, M. Buszczak, S. Morrison, and H. Sadek for critical input and advice; E. Choi for assistance with FISH; J. Xu and the CRI sequencing core for genome sequencing; N. Loof and the CRI Flow Core for cell sorting and analysis; and K. Luby-Phelps and A. Bugde for confocal imaging. We thank Alnylam's Bioinformatics, Oligo Synthesis, and RNAi Lead Discovery team for designing, generating, and screening for the Anln GalNAc siRNAs. We thank E. Olson and J. McAnally for advice and assistance with transgenic mouse generation. D.J.S. was supported by the Cancer Prevention and Research Institute of Texas (CPRIT R1212), the Welch Foundation (I-1855), and the American Cancer Society (RSG-17-012-01). X.L. is supported by CPRIT (RP150596). H.Z. was supported by the Pollack Foundation, an American Cancer Society pilot grant (IRG-02-196), an NIH/NCI R01 grant (R01CA190525), a Burroughs Welcome Career Award for Medical Scientists, a CPRIT Scholar Award (R1209), a CPRIT Individual Investigator Award (RP170267), a CPRIT Early Translation Award (DP150077), and a Stand Up To Cancer Innovative Research Grant (SU2C-AACR-IRG 10-16). Stand Up To Cancer is a program of the Entertainment Industry Foundation and its research grants are administered by the American Association for Cancer Research, the scientific partner of SU2C. Funding Information: We thank H. Yu, M. Buszczak, S. Morrison, and H. Sadek for critical input and advice; E. Choi for assistance with FISH; J. Xu and the CRI sequencing core for genome sequencing; N. Loof and the CRI Flow Core for cell sorting and analysis; and K. Luby-Phelps and A. Bugde for confocal imaging. We thank Alnylam's Bioinformatics, Oligo Synthesis, and RNAi Lead Discovery team for designing, generating, and screening for the Anln GalNAc siRNAs. We thank E. Olson and J. McAnally for advice and assistance with transgenic mouse generation. D.J.S. was supported by the Cancer Prevention and Research Institute of Texas (CPRIT R1212 ), the Welch Foundation ( I-1855 ), and the American Cancer Society ( RSG-17-012-01 ). X.L. is supported by CPRIT ( RP150596 ). H.Z. was supported by the Pollack Foundation , an American Cancer Society pilot grant ( IRG-02-196 ), an NIH/NCI R01 grant ( R01CA190525 ), a Burroughs Welcome Career Award for Medical Scientists, a CPRIT Scholar Award (R1209), a CPRIT Individual Investigator Award ( RP170267 ), a CPRIT Early Translation Award ( DP150077 ), and a Stand Up To Cancer Innovative Research Grant ( SU2C-AACR-IRG 10-16 ). Stand Up To Cancer is a program of the Entertainment Industry Foundation and its research grants are administered by the American Association for Cancer Research, the scientific partner of SU2C. Publisher Copyright: {\textcopyright} 2018 Elsevier Inc.",
year = "2018",
month = feb,
day = "26",
doi = "10.1016/j.devcel.2018.01.010",
language = "English (US)",
volume = "44",
pages = "447--459.e5",
journal = "Developmental Cell",
issn = "1534-5807",
publisher = "Cell Press",
number = "4",
}